SMAD2 and pancreatic neoplasm: To date, there are many reports regarding the TGF-β signalling pathway in pancreatic cancer (e.g. TGF-β receptor II, Smad2 and Smad4), but only a few deal with this gene’s alterations in pancreatic cancer (Li et al, 2004; Wada et al, 2004).